Trial Profile
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as per Results published in the European Journal of Cancer
- 01 Jan 2015 New trial record